Study M794
Study name | Omori W 2021 |
Title | Reduced cerebrospinal fluid levels of lysophosphatidic acid docosahexaenoic acid in patients with major depressive disorder and schizophrenia |
Overall design | The aim of this study was to investigate the levels of lysophospholipids species including lysophosphatidic acid and related metabolic enzymes, in cerebrospinal fluid of patients with major depressive disorder (MDD) and schizophrenia (SCZ). Cerebrospinal fluid was obtained from age- and sex-matched healthy controls (control group, n = 27) and patients with MDD (MDD group, n = 26) and SCZ (SCZ group, n = 27). The levels of lysophospholipids species were measured with liquid chromatography-tandem mass spectrometry. |
Study Type | Type1; |
Data available | Unavailable |
Organism | Human; |
Categories of depression | Depressive disorder; Depression; Depression; |
Criteria for depression | DSM-IV diagnosed MDD |
Sample size | 53 |
Tissue | Central; Cerebrospinal fluid; Cerebrospinal fluid; |
Platform | MS-based; LC-MS: UltiMate 3000 (Thermo Fisher Scientific) with TSQ Quantiva system; |
PMID | |
DOI | |
Citation | Omori W, Kano K, Hattori K, et al. Reduced cerebrospinal fluid levels of lysophosphatidic acid docosahexaenoic acid in patients with major depressive disorder and schizophrenia. Int J Neuropsychopharmacol. 2021 Dec 8;24(12):948-955. |
Metabolite |
